Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Assets (2016 - 2025)

Cardiff Oncology's Current Assets history spans 15 years, with the latest figure at $60.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 36.74% year-over-year to $60.1 million; the TTM value through Dec 2025 reached $60.1 million, down 36.74%, while the annual FY2025 figure was $60.1 million, 36.74% down from the prior year.
  • Current Assets for Q4 2025 was $60.1 million at Cardiff Oncology, down from $61.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $146.1 million in Q4 2021 and bottomed at $59.3 million in Q3 2024.
  • The 5-year median for Current Assets is $93.9 million (2023), against an average of $98.5 million.
  • The largest annual shift saw Current Assets soared 1150.33% in 2021 before it tumbled 36.74% in 2025.
  • A 5-year view of Current Assets shows it stood at $146.1 million in 2021, then fell by 23.84% to $111.3 million in 2022, then plummeted by 30.44% to $77.4 million in 2023, then rose by 22.79% to $95.1 million in 2024, then crashed by 36.74% to $60.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Current Assets are $60.1 million (Q4 2025), $61.8 million (Q3 2025), and $73.7 million (Q2 2025).